title: Ticagrelor: Effects Beyond the P2Y12Receptor.
abstract: Platelet P2Y12receptor inhibitors are crucial in the treatment of patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Ticagrelor is a reversibly binding, potent oral P2Y12inhibitor that also is a weak inhibitor of the equilibrative nucleoside transporter-1 pathway for cellular adenosine uptake. It is hypothesized that ticagrelor has clinically relevant "off-target" effects, independent of its effect on platelet aggregation and thrombosis. This review considers the pleiotropic effects of ticagrelor and some of the possible mechanisms related to these effects.
authors.affiliation: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. Electronic address: w.sumaya@sheffield.ac.uk.
authors.forename: Wael
authors.initials: W
authors.lastname: Sumaya
authors.affiliation: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK.
authors.forename: Robert F
authors.initials: RF
authors.lastname: Storey
mesh_terms: D054058:Acute Coronary Syndrome / Q000601:surgery*; D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007275:Injections, Intravenous; D062645:Percutaneous Coronary Intervention; D010974:Platelet Aggregation / Q000187:drug effects*; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage; D000077486:Ticagrelor
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine
keywords: Acute coronary syndrome; Adenosine; Inflammation; P2Y(12) antagonist; Ticagrelor